Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 11, 2013

View Archived Issues

Derma Sciences begins enrollment in phase III DSC-127 trial

CX3CR1 gene polymorphisms investigated in multiple sclerosis

DNA-binding protein SATB1 associated with aggressive prostate cancer

Merck & Co. prepares new BTK inhibitors

Abbott Laboratories presents novel CCR2 receptor antagonists

Spanish researchers disclose new DP2 receptor antagonists

MorphoSys divulges new bispecific monoclonal antibodies

Nihon University discloses novel apoptosis inducers

Novel DPP IV inhibitors synthesized at Boehringer Ingelheim

AstraZeneca patents new MCH1 receptor antagonists

Scientists at Janssen Pharmaceuticals present new gamma-secretase modulators

Avanir Pharmaceuticals reports interim data for AVP-786

Intellect Neurosciences begins preclinical proof-of-concept studies for TauC3

Bevacizumab improves survival in patients with cervical cancer

TGFR-1 inhibitor prevents metastasis in animal models of breast cancer

Gilead Sciences completes acquisition

Shire begins phase III study in epidermolysis bullosa

FDA issues draft guidance on developing drugs for early Alzheimer's disease

Data from phase II Reolysin trial in lung cancer reported

Glucokinase plus insulin genetic therapy cures diabetes in dogs

Phospho-p90RSK6 as a predictive marker in ER-positive breast cancer

EMA committee begins safety review of Diane-35 and generics

Bayer HealthCare to coordinate newly founded pan-European consortium

FDA approves second drug for multiple myeloma

RNL Bio seeks Korean clearance for phase II/III trials of stem cell product

Novo Nordisk receives complete response letter for Tresiba and Ryzodeg

Bayer HealthCare files applications for riociguat in U.S. and Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...